A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)

Trial Profile

A Pilot Open-Label Study to Examine the Safety and Efficacy of Oral LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Who Have Been Previously Treated With Non-LDE225 Smoothened Inhibitor(s)

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2017

At a glance

  • Drugs Sonidegib (Primary)
  • Indications Basal cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Sep 2016 Status changed from discontinued to completed.
    • 06 Nov 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top